Human cancers, including acute myeloid leukemia (AML), commonly display constitutive PI3K/AKT signaling. However, the exact role of AKT activation in leukemia and its effects on hematopoietic stem cells (HSCs) are poorly understood. 
Introduction
The PI3K/AKT pathway is central to many biological processes, including insulin metabolism, protein synthesis, proliferation, and apoptosis. Activated growth factor receptors recruit PI3K to the plasma membrane, allowing for the phosphorylation of phosphoinositides (PIP) and conversion of PIP2 to PIP3. Proteins containing pleckstrin
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From homology domains (PH) such as Akt bind PIP3 lipid products and become associated with the plasma membrane. This membrane localization allows for kinases such as PDK1 and mTOR to phosphorylate and activate AKT. Akt, a serine/threonine kinase, is the major effector of the PI3K signaling pathway, and many of its substrates regulate cell survival and growth 1 . Most significantly, dysregulation of the PI3K kinase/AKT pathway has been implicated in many human malignancies. For example, activating mutations in PIK3CA, the gene encoding the alpha catalytic subunit of PI3 kinase, have been identified in a variety of human tumors, such as breast, lung, and colon carcinomas 2 .
The same activating mutations in PI3 kinase can confer factor-independent growth and leukemogenic potential to hematopoietic cells 3 . An activating mutation in the PH domain of AKT was recently found in breast, colon, and ovarian tumors, and cooperates with
Eμmyc in a mouse model of leukemia 4 . However, similar mutations in PI3 kinase or AKT have not been identified in AML 5, 6 . Nevertheless, the constitutive phosphorylation of AKT has been detected in a large proportion of primary AML patient samples [7] [8] [9] [10] . In a subset of those cases, it has been shown that somatic mutations in tyrosine kinases, such as FLT3-ITD and BCR-ABL are responsible for AKT activation, whereas in other cases the genetic basis for AKT activation is not known 11 . Despite the prevalence of AKT phosphorylation in AML, it is not known if AKT acts as a mediator of transformation or progression in this disease.
Mice with conditional hematopoietic-specific deletion of Pten, a phosphatase that antagonizes Pi3k/Akt signaling, develop an MPD that can progresses to both AML and T-cell acute lymphoblastic leukemia (T-ALL) over several weeks 12, 13 . Paradoxically, the HSCs in these mice are driven into the cell cycle and become depleted. Rapamycin
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From rescues this stem cell defect, and prevents the development of leukemia in Pten-deficient mice 12 . Interestingly, a similar myeloproliferative phenotype and depletion of the stem cell pool occurs with combined conditional deletion of FoxO1/FoxO3/FoxO4 in the hematopoietic lineage 14, 15 . The FoxO transcription factors regulate quiescence, apoptosis, and cellular response to oxidative stress, and are degraded after phosphorylation by activated AKT. Mice with FoxO deletions do not develop AML, but do develop T cell lymphoma after several months. Furthermore, deletion of TSC1, which leads to activation of mTOR signaling, causes rapid cycling of HSCs and a buildup of reactive oxygen species, and reduces HSC self-renewal 16 . The contrasts between these phenotypes, particularly in the incidence of leukemia, suggest that Pten deletion may affect alternative downstream mediators of the PI3K/AKT pathway, or a parallel pathway, to induce AML. Similarly, the FOXOs are regulated by other pathways independently of PI3K/AKT 17 . Therefore, the specific role of AKT in leukemogenesis and HSC homeostasis has remained elusive. All of these mouse models suggest that the PI3K/AKT pathway may play an important role in both normal hematopoiesis and leukemic transformation. However, Pten, FOXO and TSC1 deletions are not commonly detected in human AML, whereas pathologic phosphorylation of AKT is highly prevalent.
We have generated a model system using constitutively active AKT to more closely mimic what has been observed in human AML. We introduced a myristoylated allele of vivo, we also demonstrate that mTOR is an important mediator of myr-AKT function both in the regulation of HSC self-renewal, and in the progression of T cell lymphoma.
Materials and Methods

Plasmid Preparation and Viral Supernatant Production
Ba/F3 cells were maintained in RPMI 1640 media with 10% FCS and either interleukin-3 (IL-3) (0.5 ng/mL; R&D Systems, Minneapolis, MN) or WEHI-conditioned media as a source of IL-3. Retroviral stocks were generated from transfection of 293T cells, and viral titers were determined as previously described 18 . The myr-AKT1 cDNA was sub cloned into the EcoRI site of the MSCV-IRES-GFP vector. Myr-AKT-IRES-GFP and IRES-GFP retroviral supernatants were produced in 293T cells using the Fugene system (Roche) as previously described 18 .
Retroviral BMT Assay
All mice were housed in a pathogen-free animal facility in microisolator cages, and experiments were conducted based on a protocol approved by the Institutional Animal
Care and Use Committee (IACUC). Murine BMT experiments were performed as previously described 18 . Wild-type 6-8 week old C57 Bl/6 donor mice were given a single IP injection of 5-FU (Sigma) at 0.15mg/g body weight on day -8. The donor mice were sacrificed at day -2, and bone marrow was harvested. After treatment with RBC lysis buffer (Puregene), the bone marrow was stimulated overnight in RPMI/10%FBS with murine IL3, IL6, and SCF. The bone marrow was then transduced twice with the 
Flow Cytometry
Bone marrow cells, splenocytes and thymocytes were harvested and subjected to red cell lysis. Fresh or frozen cells were stained with the following antibodies: Mac1-PE, Gr1-APC, c-Kit-APC, CD71-PE, Ter119-APC, B220-PE, and TCRβ-APC (BectonDickinson) and analyzed on the BD FACSCalibur instrument. ROS levels were measured by sorting LSK cells or progenitors and then staining with 5μM DCF-DA (2'-7'-dichlorofluorescein diacetate, Molecular Probes). Staining for multiparameter flow cytometry was performed as previously described 15 , and the cells were analyzed on the BD FACSAria instrument.
Colony-Forming Assays
Bone marrow and spleen cells were harvested, subjected to red cell lysis, and resuspended in IMDM/10%FBS/5% penicillin-streptomycin. Cells were plated in 
Results
Activation of AKT in hematopoietic cells causes a myeloproliferative disease
We developed a mouse model of AKT activation in the hematopoietic system using a retroviral bone marrow transplant (BMT) assay. For this assay, we used a retroviral construct encoding myristoylated AKT1 (myr-AKT) bicistronic to green fluorescent Figure 1C ). These results suggest that myr-AKT causes an expansion of immature myeloid cells in the bone marrow and spleen.
T-cell lymphoma in myr-AKT transplant recipients
By 6-8 weeks post transplant, 65% of the myr-AKT recipient mice developed a CD4+/CD8+ lymphoblastic thymic T-cell lymphoma. All of the mice that succumbed to T-cell lymphoma had a coexisting MPD. These animals had markedly enlarged
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From thymuses ( Figure 2A ). Flow cytometric analysis of thymocytes from mice with T cell lymphoma revealed that most GFP+ cells in the thymus were CD4/CD8 double positive, and a few GFP+ CD4+/CD8+ cells were also seen in the bone marrow and spleen ( Figure   2B ). These lymphoblasts also invaded other organs, such as the lung, heart, bone marrow, and muscle ( Figure 2C ). The T-cell disease was transplantable to secondary recipients, which became ill and died with a mean latency of 30 days ( Figure 3C ). The transplanted disease was a more aggressive T-ALL, with CD4/CD8+ lymphoblasts infiltrating the BM, liver, spleen, and kidney (Supplementary Figure S2A and S2B).
Southern analysis of thymocyte genomic DNA from myr-AKT mice with T cell lymphoma using a GFP-specific probe reveals that the T-cell lymphoma induced by myr-AKT is a monoclonal or oligoclonal disease, suggesting that retroviral integration sites may play a role in disease initiation or progression (Supplementary Figure S2C) .
AML in myr-AKT transplant recipients
Approximately 10% of the myr-AKT transplant recipients developed AML without any evidence of preexisting MPD. In these animals, disease onset was observed at 4-7 weeks post-transplant. Myeloblasts were observed effacing the bone marrow, spleen and liver architecture ( Figure 3A ). The GFP + population was composed of immature undifferentiated cells expressing c-Kit and CD71, low levels of the myeloid markers Mac1 and Gr1, but not the lymphoid markers B220 or TCRβ ( Figure 3B ). AML blasts in the spleen, liver, and bone marrow were myeloperoxidase negative and terminal deoxynucleotidyl transferase negative (data not shown). Therefore, the immunophenotype of this leukemia is that of an undifferentiated AML (M0 in FAB 
Impaired engraftment in myr-AKT mice
We were surprised to find that, despite the ability of the myr-AKT-IRES-GFP retrovirus to cause MPD and AML in recipient mice, the percentage of GFP + cells was consistently lower in the bone marrow of sick myr-AKT recipient mice when they were sacrificed at 6-8 weeks post-transplant compared to GFP controls ( Figure 4A ). This could not be explained by differences in transduction efficiency between the two retroviruses, as the and data not shown). We did observe an increase in apoptosis in the GFP+ LSK For personal use only. on July 15, 2017. by guest www.bloodjournal.org From population in myr-AKT mice sacrificed at 6-8 weeks, suggesting that this may be a mechanism for the impaired reconstitution we observed ( Figure 4D ). To examine the clonogenic capacity and in vitro self-renewal activity of bone marrow and spleen cells isolated from diseased myr-AKT mice, we performed methylcellulose plating assays in M3434 media. Splenocytes from myr-AKT recipient mice produced more myeloid colonies initially, with a predominance of granulocyte-macrophage (GM) colonies, while bone marrow cells yielded approximately the same number of colonies ( Figure 4E , F, Tables 2-3 ). However, both splenocytes and bone marrow cells from myr-AKT mice failed to replate past 2 rounds ( Figure 4E,F) . These results reveal that while myr-AKT increases the clonogenic capacity of splenocytes, it does not confer in vitro self-renewal properties.
Short-term elevation of AKT signaling causes expansion of the LSK compartment and increased cycling of LSK cells
To better understand the effects of constitutive AKT activation on stem cell function, we utilized a tamoxifen-inducible MSCV-myr-AKT-Estrogen Receptor-IRES-Thy1.1 (myr-AKT-ER) retrovirus in the BMT system to analyze the effects of short-term AKT signaling on the stem and progenitor cell compartments. Thy1.1 is expressed at very low levels in the LSK and progenitor populations in C57 Bl/6 mice, so it can be used as a marker in this system (Supplementary Figure S4B) . Mice transplanted with bone marrow expressing myr-AKT-ER or control MSCV-Thy1.1 retrovirus were injected with tamoxifen IP daily for three days after the four week engraftment period to induce myr-AKT expression, and then were sacrificed and analyzed on the fourth day. Interestingly, 
Decreased cobblestone formation by myr-AKT-transduced bone marrow
Since mice transplanted with myr-AKT-expressing bone marrow become ill and die by 6-8 weeks after transplant, we were unable to perform the traditional 16-week competitive repopulation assay to assess long-term HSC function in vivo. Therefore, we utililized the in vitro long-term culture-initiating cell (LTC-IC) assay to examine the long-term stem
cell activity of myr-AKT transduced bone marrow. Cobblestones that remain after 4 weeks in the co-culture assay have been previously shown to contain long-term stem cell activity 21 . In this assay, bone marrow transduced with myr-AKT-GFP or MIG retrovirus was sorted for GFP + cells, and then 500,000 GFP-sorted cells were co-cultured for 4
weeks with irradiated OP9 stromal cells. The cultures were examined at two weeks and four weeks for cobblestone formation. After four weeks, the contents of each well were plated into M3434 methylcellulose media, and colonies were counted one week later.
We found that bone marrow cells transduced with myr-AKT were able to form cobblestones initially, but very few cobblestones were observed after four weeks (data not shown). Therefore, the number of colonies in methylcellulose from myr-AKT bone marrow seen at 5 weeks was greatly reduced compared with the colonies from control vector bone marrow ( Figure 6A ). Taken together, these results demonstrate that myr-AKT affects both short-term HSC function and long-term HSC activity based on the LTC-IC assay.
Increased levels of ROS cannot explain the impaired HSC function in myr-AKT mice
In mice with deletions of the FOXO transcription factors, which are important targets of AKT, the LSK compartment is depleted through increased cycling and apoptosis 15 . In these mice, elevated levels of ROS were demonstrated as a mechanism for the HSC exhaustion phenotype. We decided to examine ROS levels using dichloro-fluorescein acetate (DCF-DA) staining of LSK cells and progenitors from myr-AKT-ER transplant mice, to determine whether increased oxidative stress is a likely mechanism to explain the HSC phenotype we observe. Surprisingly, we did not observe any statistically Figure 6A ). This suggests that oxidative stress may not be the most important mechanism for HSC extinction in the myr-AKT model system.
Rapamycin rescues cobblestone formation by myr-AKT transduced bone marrow
Another important pathway downstream of AKT signaling is the mTOR pathway, which can control translation and cell growth when activated. The ability of rapamycin, an inhibitor of mTOR, to rescue both the disease phenotype and the HSC phenotype of mice with a conditional deletion of Pten suggests that the mTOR pathway is also important in modulating Pten-deficient HSC function 12 . In order to determine whether activation of the AKT pathway leads to a reduction in self-renewal through activation of the mTOR pathway, we added rapamycin in the LT-IC assay. Interestingly, we found that rapamycin partially rescued cobblestone formation and colony formation by myr-AKT bone marrow ( Figure 6A ).
Rapamycin treatment causes increased survival in myr-AKT mice
Rapamycin has been reported to inhibit the growth and survival of leukemia cells, and mTOR inhibitors have demonstrated activity in preclinical studies and in early clinical trials in patients with hematologic malignancies 12, [22] [23] [24] [25] [26] .
To determine whether the mTOR
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From axis is important for the survival of leukemic cells in vivo in our system, we treated myr-AKT transplant mice with rapamycin daily starting at 4 weeks post-transplant. We found that rapamycin significantly increased the latency of the disease in myr-AKT mice compared with vehicle treatment ( Figure 7A ). When we examined organ weights and performed flow cytometry analysis of bone marrow and spleens from rapamycin-treated myr-AKT animals, we found that rapamycin decreased the incidence of thymic T cell lymphoma, with a trend towards decreased thymus weights, but did not affect the 
Discussion
AKT is constitutively phosphorylated in AML patient samples, but the clinical significance of this activation is unknown. Our murine BMT with AKT activation in the hematopoietic system reveals that expression of myr-AKT is sufficient to induce MPD and T cell lymphoma with high frequency, and AML with a lower penetrance.
Therefore, phosphorylation of AKT is not simply a marker seen in AML blasts, but is an important mechanism of transformation. The MPD phenotype we observe in myr-AKT mice is consistent with the recently reported role of AKT in promoting neutrophil and monocyte development 27 . However, AML is an infrequent event in our activated AKT model. This contrasts with the Pten deletion mouse model, in which a preceding MPD rapidly progresses to either AML or T-ALL in equal proportions 12, 13 . There are several The lymphoblastic CD4+/CD8+ T cell lymphoma we observe in myr-AKT mice is consistent with previous studies in which myr-AKT was expressed in thymocytes using
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From a T-cell-specific Lck promoter 30, 31 . Likewise, mice with Pten deletions develop T-ALL, and mice with FOXO deletions develop T cell lymphoma with a long latency. This observation is also consistent with the recent report of frequent alterations in AKT and other members of the PI3K/AKT pathway in human T-ALL 32 . It is unclear why we observe a higher penetrance of T cell lymphoma than AML in myr-AKT mice, but our Southern analysis of T-cell lymphoma samples from myr-AKT mice suggests that additional mutations introduced by retroviral insertion may play a role.
Due to the increased cycling and apoptosis of LSK cells observed in myr-AKT mice and the impaired engraftment and cobblestone formation of myr-AKT expressing bone marrow, we conclude that activated AKT is unfavorable for HSC function.
Additional molecular events may be necessary to compensate for the deleterious effects of AKT activation on the HSCs to allow for AML to develop. The HSC phenotype that we observe in myr-AKT mice closely resembles the HSC phenotype of mice that harbor conditional deletion of FoxOs in the hematopoietic lineage 12, 13, 15 . For example, the MPDs observed in both mouse models, and increased cycling with a paradoxical increase in apoptosis in the LSK cells is observed both with constitutive AKT activation and with FoxO loss. This result is surprising, given the previously described role of AKT in inhibiting apoptosis. The effect seen on stem cells in this study may be due to supraphysiologic levels of activation of AKT signaling in these cells, and to the particular sensitivity of HSCs to tight regulation of AKT signaling. Taken together, these results argue that the FoxO transcription factors contribute to maintenance of HSC homeostasis, but not to leukemogenesis. However, we did not find any change in ROS levels in LSK cells or progenitors, and the antioxidant N-acetyl Cysteine was unable to rescue The role for mTOR signaling has been shown to be essential for LSKs in the context of Pten deletion 12, 13 . Furthermore, the LSK extinction phenotype of Pten-deleted mice could be rescued by treatment with rapamycin. This is consistent with a recent study in which TSC1 deletion was found to induce rapid cycling in HSCs, leading to increased frequency of HSCs and impaired reconstitution 16 . Consistent with these studies, we observed partial rescue of cobblestone formation of myr-AKT-expressing bone marrow by rapamycin, suggesting that tight regulation of mTOR signaling is necessary for cobblestone formation.
The inhibition of mTOR is being actively pursued as a strategy for the treatment of both AML and T-ALL, with moderate success in preclinical and early clinical trials 12, 22, 25, 26 . Consistent with these prior observations, we did observe a significant survival benefit when myr-AKT mice were treated with rapamycin starting at four weeks post-transplant. However, we only observed a decrease in the incidence of thymic T cell lymphoma, with no change in the incidence or severity of MPD or AML. Together with the fact that we detected a higher level of ribosomal protein S6 phosphorylation in myr-AKT thymocytes than in myr-AKT splenocytes, this observation suggests a stronger dependence of T cells than myeloid cells on mTOR signaling. The lack of effect of rapamycin on the MPD and AML disease in our model contrasts with the antileukemic effect of rapamycin seen in the Pten deletion model 12 . However, this may be explained by a difference in the timing of rapamycin administration. In Pten-deleted mice,
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From rapamycin was given before disease was established, whereas we began treating myr-AKT mice four weeks after BMT. In fact, when rapamycin was administered after disease initiation in Pten-deleted mice, leukemia progression was unaffected 12 .
Interestingly, rapamycin does still affect the progression of T cell lymphoma in our myr-AKT model. However, we observed a few cases of resistant T cell lymphoma in rapamycin-treated animals. This resistance to rapamycin may be explained by the activation of alternative pathways through either retroviral integration or de novo mutations, and could be an interesting avenue of future investigation.
Taken together, our analysis of mice with activated AKT in the hematopoietic system has revealed that elevated AKT signaling plays an important role in both myeloid and lymphoid leukemogenesis and in HSC maintenance. In addition, this study has important implications for the utility of AKT and mTOR as targets for leukemia therapy.
This myr-AKT BMT model of disease will be a useful model system for examination of the resistance mechanisms to mTOR inhibitors, as well as for testing other inhibitors of AKT signaling in leukemia.
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